ADAP 4Q24 Earnings: EPS Miss on 1x Restructuring/Impairment Costs Potential Capital Raise Adds Risk to the Story
Key 4Q24 takeaways include: 1) Tecelra launch ahead of expectations based on the number of patients apheresed thus far and ATCs up and running,...
182 Views
ADAP: 4Q24 Business Update
Zacks Small-Cap Research Note for Adaptimmune Therapeutics plc (ADAP)
226 Views
ADAP 2Q24 Earnings: Tecelra FDA Approval + Capital Reload
Key 2Q24 takeaways include: 1) recent FDA approval of Tecelra (afami-cel) triggers immediate onboarding of Authorized Treatment Centers (ATCs),...
170 Views
ADAP: Initiating Coverage of Leading T-Cell Therapy Company
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a biopharmaceutical company focused on designing, developing, and delivering innovative cell...
197 Views
Biopharma Week in Review
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.
48 Views
No more insights